Johnson & Johnson (JNJ)

JNJ (NYSE:Drugs) EQUITY
$118.60
neg -0.11
-0.09%
Today's Range: 118.33 - 119.21 | JNJ Avg Daily Volume: 6,922,600
Last Update: 08/25/16 - 3:59 PM EDT
Volume: 5,558,582
YTD Performance: 15.57%
Open: $118.90
Previous Close: $118.71
52 Week Range: $89.90 - $126.07
Oustanding Shares: 2,735,876,843
Market Cap: 326,773,130,128
6-Month Chart
TheStreet Ratings Grade for JNJ
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 7 7
Moderate Buy 2 2 2 2
Hold 8 9 8 8
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.22 2.26 2.22 2.22
Latest Dividend: 0.80
Latest Dividend Yield: 2.68%
Dividend Ex-Date: 08/19/16
Price Earnings Ratio: 21.76
Price Earnings Comparisons:
JNJ Sector Avg. S&P 500
21.76 22.50 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
5.34% 27.89% 34.27%
GROWTH 12 Mo 3 Yr CAGR
Revenue -5.70 0.00 0.01
Net Income -5.60 0.50 0.13
EPS -3.90 0.40 0.12
Earnings for JNJ:
EBITDA 22.04B
Revenue 70.07B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $1.63 $1.58 $6.68 $7.09
Number of Analysts 10 8 10 12
High Estimate $1.67 $1.64 $6.70 $7.31
Low Estimate $1.59 $1.55 $6.67 $6.89
Prior Year $1.49 $1.44 $6.20 $6.68
Growth Rate (Year over Year) 9.53% 9.81% 7.82% 6.07%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Aug 25, 2016 | 7:35 AM EDT
It could well be the stock market, not the Fed, that is driving our retail and services.
By

Paul Price

 | Aug 19, 2016 | 7:00 AM EDT
Its long-term reputation appears to be supporting the shares far more than they deserve.
By

Jim Cramer

 | Aug 17, 2016 | 8:09 AM EDT
Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.
By

Anders Keitz

 | Jul 29, 2016 | 4:20 PM EDT
Zimmer Biomet is on track to return to growth, which could signal more mergers and acquisitions within the industry.
By

Casey Hoerth

 | Jul 27, 2016 | 10:00 AM EDT
Time to lock in gains in JNJ.
By

Marco Mazzocco

 | Jul 22, 2016 | 9:00 AM EDT
There are plenty of doubters about the market and its record highs.
By

James Passeri

 | Jul 20, 2016 | 9:21 AM EDT
Valeant could rake in more than $1 billion annually in new sales after FDA approval of a key drug.
By

Jim Cramer

 | Jul 19, 2016 | 1:09 PM EDT
It depends on the type of test and who's doing the grading.
By

James Passeri

 | Jul 19, 2016 | 8:18 AM EDT
Netflix underwhelmed analysts as subscriber growth came up short.
By

Jim Cramer

 | Jul 18, 2016 | 6:00 AM EDT
Let me give you the unassailable themes.
We have followed all areas of the Healthcare industry for decades. And while there are lik...
Shares of Dollar General (DG) got hammered today after fiscal Q2 EPS came in at $1.08 vers...
Before the open today, I noted to our members that crude oil is starting to look and act l...
Stocks continue to meander in very narrow ranges as investors appear hesitant to make any ...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.